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A Phase II First-Line Study of Gemcitabine, Carboplatin,
and Bevacizumab in Advanced Stage Nonsquamous Non-
small Cell Lung Cancer
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Alex McMillan,¶ Atul Kumar,* Gary Zhao,§ Sukhmani Padda,* Lisa Zhou,
Melanie San Pedro-Salcedo,* A. Dimitrios Colevas,* and Heather A. Wakelee, MD*
Background: Bevacizumab improves responses and progression-
free survival when added to first-line paclitaxel/carboplatin or cis-
platin/gemcitabine for patients with advanced nonsquamous non-
small cell lung cancer. This study was designed to evaluate toxicities
and efficacy of gemcitabine/carboplatin/bevacizumab.
Methods: Patients with untreated advanced nonsquamous non-small
cell lung cancer, with no evidence of brain metastases and not on
anticoagulation were eligible. Patients received gemcitabine 1000
mg/m2 on days 1 and 8; carboplatin area under the curve 5 day 1;
and bevacizumab 15 mg/kg day 1 every 3 weeks for up to six cycles.
Bevacizumab was then continued every 3 weeks until disease
progression or unacceptable toxicity.
Results: From July 2006 to December 2008, 48 patients were
enrolled: 23 (48%) men, 25 (52%) women, and 19 (40%) never
smokers. One patient never received therapy and is not included in
the analysis. Median cycle number was 8 (1–42) with 37 patients
(78.7%) completing 4 cycles of three drugs. Dose reductions
occurred in 34 (72.3%) patients. Grade 3/4 toxicities included
neutropenia (47%/15%), thrombocytopenia (11%/15%), anemia
(6%/0%), dyspnea (6%/2%), bacterial pneumonia (4%/0%), and
hypertension (4%/2%). No neutropenic fevers occurred. One patient
died of hemoptysis. Grade 3 bleeding occurred in three other
patients. There were seven (14.9%) partial responses. Median time
to first event (progression/death/toxicity requiring discontinuation)
was 6.4 months (95% confidence interval: 4.8–7.9 months). The
median overall survival (OS) was 12.8 months (95% confidence
interval: 10.0–16.5). The OS is 57% at 1 year and 10% at 2 years.
Conclusions: Although perhaps skewed by a high proportion of
nonsmokers and women, treatment with gemcitabine/carboplatin/
bevacizumab has an acceptable toxicity profile with promising
median OS despite a low response rate.
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Lung cancer is the leading cause of cancer-related death inthe United States, with an estimated 219,440 new cases
and 159,390-related deaths in 2009.1 Despite advances in
treatment, nearly 80% of lung cancer cases are diagnosed at
advanced stages (IIIB or IV), and the 5-year survival rate has
not exceeded 15%.1,2 Meta-analyses have definitively shown
that the use of palliative chemotherapy with supportive care
improves survival compared with supportive care alone in
patients with advanced non-small cell lung cancer (NSCLC).3
Schiller et al. compared three chemotherapy regimens (cis-
platin plus gemcitabine, cisplatin plus docetaxel, and carbo-
platin plus paclitaxel) to a standard reference regimen of
cisplatin plus paclitaxel and found comparable efficacy; no
differences in response rate (RR), median, and 1-year sur-
vival among treatment arms. Only the toxicity profile varied
among the different regimens.4 Now, platinum-doublet che-
motherapy combinations are the standard of care for first-line
treatment of metastatic NSCLC. Since 2006, bevacizumab
has been approved as an addition to chemotherapy for
nonsquamous (NSq)-NSCLC in combination with carbopla-
tin and paclitaxel in the United States and more recently in
combination with any chemotherapy doublet in the European
Union based on randomized phase III data looking at standard
platinum doublets with or without the agent.5–8 At the time
this trial was designed, carboplatin/gemcitabine was a com-
mon first-line regimen based on similar efficacy with a
different toxicity profile, including decreased risk of hyper-
sensitivity reaction, decreased neuropathy, and decreased
alopecia but increased myelosuppression compared with car-
boplatin/paclitaxel.9–12 Given the promising data seen at the
time of trial conception with carboplatin/paclitaxel/bevaci-
zumab, this study was designed to evaluate progression-free
survival (PFS), toxicities, and adverse events (AEs) of a
*Division of Oncology, Department of Medicine; ¶Division of Health
Research and Policy, Department of Biostatistics, and Division of Thoracic
Surgery, Department of Medicine, Stanford Cancer Center, Stanford Uni-
versity, Stanford, California; †Respiratory Diseases Department, University
Hospital, Vandoeuvre-Le`s-Nancy, France; ‡Division of Oncology, Depart-
ment of Medicine, Veterans Administration Medical Center, Palo Alto; and
§Santa Clara Valley Medical Center, San Jose, California.
Disclosure: Health Wakelee, MD, received research support, paid to Stanford
University, from both Genentech and Eli Lilly and Company to support
this trial and others.
Address for correspondence: Heather Wakelee, MD, Stanford University and
Cancer Center, 875, Blake Wilbur Dr, Stanford, CA 94305-5826. E-mail:
hwakelee@stanford.edu
Copyright © 2010 by the International Association for the Study of Lung
Cancer
ISSN: 1556-0864/10/0511-1821
Journal of Thoracic Oncology • Volume 5, Number 11, November 2010 1821
combination of gemcitabine, carboplatin, and bevacizumab
and to estimate event free and overall survival (OS) in
patients with newly diagnosed metastatic NSCLC that was
previously untreated and nonsquamous in histology.
PATIENTS AND METHODS
This study is a phase II, open-labeled, single-arm,
multicenter study of bevacizumab in combination with
gemcitabine and carboplatin in patients with newly diag-
nosed NSCLC (excluding squamous cell carcinoma). All
patients signed informed consent that had been reviewed
by institutional review boards at each of the three partic-
ipating institutions.
Patients
Male and female patients with a recent diagnosis of
advanced NSCLC, stage IIIB with malignant pleural effusion
and stage IV, were included in this study. To be eligible, the
patients needed to have a NSq-NSCLC with measurable or
evaluable disease. No prior systemic therapy for advanced
NSCLC was allowed, and prior therapy for early stage dis-
ease with one regimen was acceptable if it was completed at
least 6 months before study entry. Palliative radiotherapy to
painful bony metastases was permitted before study entry if
completed before initiation of study treatment, and there were
no residual sequelae of therapy such as bone marrow sup-
pression. A life expectancy of at least 3 months was required.
All patients needed to have an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1 and an age of
18 years. Patients had normal organ and marrow function
as follows: leukocytes 3000/l, absolute neutrophil count
1500/l, platelets 100,000/l, total bilirubin within nor-
mal institutional limits, aspartate aminotransferase (AST)
(SGOT)/alanine aminotransferase (ALT)(SGPT) 2.5  in-
stitutional upper limit of normal, creatinine of 2.0 or creati-
nine clearance 30 ml/min/1.73 m2.
Exclusion criteria were as follows: any prior systemic
treatment for advanced NSCLC; known brain metastases;
prior treatment with bevacizumab; current, recent (within 4
weeks of the first infusion of this study), or planned partici-
pation in any other experimental drug study; concomitant
chemotherapy, radiotherapy or investigational agents; evi-
dence of bleeding diathesis or coagulopathy; use of antico-
agulant agents including warfarin, heparin, aspirin, non-
steroid antiinflammatory drugs; pregnant (positive pregnancy
test) or lactating women; major surgical procedure, open
biopsy, or significant traumatic injury within 28 days; minor
surgical procedures, fine needle aspirations or core biopsies
within 7 days; urine protein:creatinine ratio 1.0 at screen-
ing; history of abdominal fistula, gastrointestinal perforation,
or intraabdominal abscess within 6 months; serious, nonheal-
ing wound, ulcer, or bone fracture; lung carcinoma of squa-
mous cell histology or any histology in close proximity to a
major vessel, or with significant cavitation; history of hemop-
tysis; significant comorbidities (blood pressure superior of
150/100 mmHg, unstable angina, New York Heart Associa-
tion grade II or greater congestive heart failure, history of
myocardial infarction within 6 months, history of stroke
within 6 months, and clinically significant peripheral vascular
disease); psychiatric illness and social situations that would
limit compliance with study requirements; another active
malignancy except for nonmelanoma skin cancers; and in-
ability to comply with study and/or follow-up procedures.
Study Treatment
All patients were treated with intravenous bevacizumab
at 15 mg/kg every 3 weeks and carboplatin at an area under
the curve (AUC) of 5 given intravenously over 30 to 60
minutes on day 1 (same day as bevacizumab) every 3 weeks
plus gemcitabine at 1000 mg/m2 given intravenously over 30
minutes on days 1 and 8 every 3 weeks. Carboplatin was
administered before gemcitabine infusion. Bevacizumab was
administered 1 hour after chemotherapy infusion. Bevaci-
zumab was initially given over 90 minutes with observation
in case of reaction to the medication. If it was tolerated well
in the first cycle, the second cycle infusion period was
reduced to 60 minutes, and all subsequent infusions were
reduced to 30 minutes. Patients could receive a maximum of
six cycles of chemotherapy, but treatment with bevacizumab
could continue as long as patients had no evidence of pro-
gressive disease and no significant treatment-related toxici-
ties. Standard antiemetics were allowed.
Study Assessments
The primary objective of this study was the evaluation
of PFS. The secondary objectives were the evaluations of the
OS, and the RR per RECIST criteria, and the identification of
the safety of this combination regimen. Toxicity grading was
performed according to the National Cancer Institute’s Com-
mon Toxicity Criteria for Adverse Events, version 3.0. To
assess response to treatment, follow-up imaging (computed
tomography scans) were obtained after every two cycles.
Laboratory evaluations were performed weekly for the first 6
weeks, then every 3 weeks at the time of treatment.
Dose Modifications
No reductions in the bevacizumab dose were allowed.
If serious AEs (bleeding and proteinuria) occurred, bevaci-
zumab was held, and the dose would remain the same after
the AEs were resolved. Standard dose modifications of car-
boplatin and gemcitabine were allowed based on hematologic
and other criteria. Before the start of each cycle, absol-
ute neutrophil count had to be 1500/l and platelets
100,000/l. If absolute neutrophil count was between 1000
and 1500/l and platelets were between 75,000 and 100,000/
l, the treatment was delayed by 1 week and the gemcitabine
was reduced by 20%. If absolute neutrophil count was
1000/l and platelets were 75,000/l, the treatment was
delayed by 1 week and the carboplatin and the Gemcitabine
were reduced by 20%. Granulocyte colony-stimulating factor
use was allowed after documented neutropenia.
Statistical Methods
The PFS was defined as the duration of time from start
of treatment to time of documented progression or death.
Assessment of safety and evaluation of OS and response
(measured according to the RECIST criteria) were also de-
termined as secondary efficacy variables. Every patient, who had
at least one cycle, was included in the analysis of the safety.
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Patients were monitored for systemic, renal, gastrointestinal,
hematologic, neurologic, liver, hemoptysis, examination and
thromboembolic toxicities, and laboratory tests were (CBC,
metabolic panel, calcium, magnesium, and liver function tests)
performed weekly for the first 6 weeks and then every 3 weeks
on the days of treatment with Avastin. In addition, patients were
seen in the clinic for history and physical examination and
assessed for side effects and toxicities every week for the first 6
weeks and then every 3 weeks on the days of treatment. The
methods of Kaplan-Meier were used to determine PFS and OS.
Patients who had not progressed were censored for the analysis
of PFS, and patients who had not died or were lost to follow-up
were censored for the analysis of OS. We planned to enroll 50
patients to detect an improvement in PFS of 2.5 months com-
pared with the ECOG trial E4599.7 The alpha risk was 5%.
RESULTS
Baseline Characteristics
From July 2006 to December 2008, accrual was com-
pleted with 48 patients enrolled with a median age of 59 years
(35–81), all with measureable disease. The median follow-up
was 13.6 months (0.23–41.6). A total of 23 (47.9%) men and
25 (52.1%) women were included, and 19 (40%) patients
were never smokers (Table 1), reflective of the patient pop-
ulation at the enrolling institutions. One patient died before
receiving therapy and is not included in the analysis. Histol-
ogies were 30 (63.8%) adenocarcinomas, four (8.5%) bron-
chioloalveolar carcinoma, and 13 (27.7%) NSCLC not oth-
erwise specified. Eight patients had stage IIIB with a
malignant effusion, and 39 had stage IV disease. After dis-
ease progression, 27 patients had a second line of chemother-
apy, and 13 had a third line, mostly erlotinib, pemetrexed, or
other trial agents ongoing in the treating centers.
Of the 47 evaluable patients, 37 patients (78.7%) com-
pleted four cycles or more of the three drugs. The median
number of total cycles (including bevacizumab alone after cycle
6) was 8 (1–42). The median number of cycles of chemotherapy
alone was 6 (1–6), and the median number of bevacizumab
alone was 4.5 (0–36). Dose reductions occurred in 34 (72.3%)
patients, primarily for hematologic toxicity. Thirty-four patients
(72.3%) switched to single-agent bevacizumab after completion
of four or six cycles of combination therapy at the discretion of
the treating physician (Table 2). Two patients withdrew consent
after 8 months and 11 months of treatment.
Safety and Tolerability
The most frequent grade 3/4 AEs were neutropenia (47%/
15%), thrombocytopenia (11%/15%), anemia (6%/0%), dys-
pnea (6%/2%), hypertension (4%/2%), proteinuria (2%/0.0%),
and transaminitis (2%/0.0%). No patients were hospitalized
for neutropenic fever (Table 3). One patient died of hemop-
tysis with untreated and unsuspected invasive pulmonary
aspergillosis found postmortem eroding into blood vessels.
Other bleeding included one case of grade 3 epistaxis, one
case of grade 3 hemorrhoidal bleeding, and one case of grade
3 ecchymosis. One grade 3 wound dehiscence and one grade
4 myocardial infarction occurred in treated patients. Common
grade 1/2 AEs included fatigue, hypertension, anemia, con-
TABLE 2. Characteristics of Treatment with the Study Drugs
Characteristics Patients, n  47 (%)
Number of cycles
Median 8
Range 1–42
Treatment interruption
Disease progression 32 (68.1)
Adverse events or toxicity 7 (14.9
Dose reduction 34 (72.3)
GSCF 7 (14.9)
GSCF, granulocyte colony-stimulating factor.
TABLE 3. Main Adverse Events
Adverse Events Grade 1⁄2, n (%) Grade 3, n (%) Grade 4, n (%)
Neutropenia 22 (46.8) 22 (47.0) 7 (15.0)
Thrombocytopenia 20 (42.5) 5 (11.0) 7 (15.0)
Anemia 22 (46.8) 3 (6.4) 0 (0.0)
Nausea 22 (46.8) 0 (0.0) 0 (0.0)
Constipation 23 (48.9) 0 (0.0) 0 (0.0)
Fatigue 30 (63.8) 1 (2.0) 0 (0.0)
Dyspnea 11 (23.4) 3 (6.4) 1 (2.0)
Epistaxis 16 (34.0) 1 (2.0) 0 (0.0)
Hypertension 23 (48.9) 2 (4.0) 1 (2.0)
Proteinuria 18 (38.3) 1 (2.0) 0 (0.0)
Transaminitis 17 (36.2) 1 (2.0) 0 (0.0)
TABLE 1. Baseline Patients’ Characteristics
Characteristics Patients, n  47 (%)
Sex
Male 22 (46.8)
Female 25 (53.2)
Age (yr)
Median 59
Range 35–81
ECOG
0 3 (6.4)
1 44 (93.6)
Smoking status
Never smokers 19 (40.4)
Current smokers 7 (14.9)
Exsmokers 21 (44.7)
NSCLC histology
Adenocarcinoma 30 (63.8)
BAC 4 (8.5)
Other 13 (27.7)
Disease stage
IIIB 8 (17.0)
IV 39 (83.0)
Second line 27 (57.4) (9 erlotinib, 14 pemetrexed, and 4 other)
Third line 13 (27.6) (5 erlotinib, 4 pemetrexed, and 4 other)
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer;
BAC, bronchioloalveolar carcinoma.
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stipation, nausea, transaminitis, and epistaxis. Seven patients
were discontinued for toxicity (infection and neutropenia,
hemoptysis, heart failure, liver dysfunction, uncontrollable
blood pressure, three consecutive dose reductions for neutro-
penia, and blood clot) (Table 2).
Efficacy
In 47 evaluable patients, seven (14.9%) partial re-
sponses and 34 (72.3%) stable disease were documented at
the first follow-up. The median PFS was 8.7 months (7.8–
17.9) (Figure 1). Median time to first event (progression/
death/toxicity requiring discontinuation) was 6.4 months
(95% confidence interval [CI]: 4.8–7.9).
On December 31, 2009, each patient had completed at
least 1 year of follow-up, and only one patient continued on
active therapy with bevacizumab. At time of data lock at the
end of December 2009, 32 patients (68%) had died. The
median OS was 12.8 months (95% CI: 10.0–16.5) (Figure 2).
The 1 and 2 years OS were 57% and 10%, respectively.
DISCUSSION
This study analyzing the efficacy and the safety of a
combination regimen of carboplatin, gemcitabine, and bev-
acizumab in newly diagnosed, untreated, advanced stage
NSq-NSCLC found a median OS of 12.8 months and a PFS
of 8.7 months. The combination is well tolerated with mini-
mal thrombocytopenia and limited bleeding. Neutropenia was
the most common AE necessitating dose reduction. Throm-
bocytopenia rates were lower than anticipated. No unex-
pected toxicities were encountered.
Bevacizumab was approved for the treatment of meta-
static NSCLC in 2006 based on the E4599 trial. The ECOG
4599 trial evaluated a combination of carboplatin (AUC  6
every 3 weeks) and paclitaxel (200 mg/m2 every 3 weeks) for
six cycles with or without bevacizumab (15 mg/kg every 3
weeks) in patients with untreated advanced NSq-NSCLC.7
Because of the risk of bleeding, this trial excluded patients
with squamous cell histology, brain metastases, anticoagula-
tion therapy, and history of gross hemoptysis, a population
similarly excluded in our trial. The study enrolled 878 pa-
tients and found an increase in median survival (10.3 versus
12.3 months; p  0.003), PFS (4.5 versus 6.2 months; p 
0.001), and RR (15% versus 35%; p  0.001) in favor of the
bevacizumab arm. In this trial, the most common AE was
bleeding in the bevacizumab arm (0.7% versus 4.4%; p 
0.001) with other AEs including grade 3 hypertension (1%
versus 7%) and grade 4 neutropenia (17% versus 26%) in the
placebo arm and bevacizumab arm, respectively (p  0.05).
The Avastin in Lung Cancer (AVAIL) trial included
patients with untreated or recurrent NSq-NSCLC, without brain
metastasis or tumor invasion into major vessels.6 In this trial,
1043 patients were enrolled in three arms, and all patients
received cisplatin and gemcitabine with placebo or bevacizumab
at 7.5 or 15 mg/kg every 3 weeks until disease progression. An
improvement in PFS was observed in both bevacizumab arms
(6.7 versus 6.1 months in the 7.5 mg/kg and placebo arms,
respectively, p  0.003 and 6.5 versus 6.1 months in the 15
mg/kg and placebo arms, respectively, p  0.03). The RR was
also significantly improved in the bevacizumab arms (30%
versus 34% versus 20% in 15 mg/kg, 7.5 mg/kg, and placebo
arms, respectively). This trial did not find a OS benefit with the
drug but had a remarkable OS exceeding 13 months in all arms.13
Bevacizumab has been tested in combination with other
chemotherapies in phase II trials with similarly encouraging
results. A recent phase II trial of 51 patients with recurrent or
newly diagnosed advanced NSCLC treated with carboplatin
(AUC  6), pemetrexed (500 mg/m2), and bevacizumab (15
mg/kg) every 3 weeks followed by a maintenance of pem-
etrexed and bevacizumab at the original doses found an
overall RR of 55% (95% CI: 41–69%) including one patient
with a complete response. The median PFS and OS were 7.8
months (95% CI: 5.2–11.5 months) and 14.1 months (95%
FIGURE 1. Progression-free survival according to a Kaplan-
Meier method.
FIGURE 2. Overall survival according to a Kaplan-Meier
method.
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CI: 10.6–19.6 months), respectively.14 Other combinations
such as gemcitabine/oxaliplatin/bevacizumab have produced
similarly high overall RR (43%) and OS (13.7 months) with
minimal bleeding complications.15,16
Gemcitabine is an active agent in NSCLC, with single-
agent treatment producing RR of approximately 20% and me-
dian survivals of approximately 7 to 9 months.17,18 Its efficacy in
combination with platinum is also well established. The regimen
in this study was based on positive results from a phase III trial
comparing single-agent gemcitabine (1250 mg/m2 days 1 and 8)
versus carboplatin (AUC  5 day 1 every 21 days) plus
gemcitabine (1250 mg/m2 days 1 and 8) in advanced NSCLC.
This trial included 334 patients and showed superiority of the
combination arm with a RR of 30%, median TTP of 5.7 months,
and OS of 10.0 months. The main AEs were grade 3/4 neutro-
penia (30%/2%) and thrombocytopenia (24%/24%).18 We chose
a slightly lower dose of gemcitabine for this trial of 1000 mg/m2
because of concern of additionally neutropenia and higher bleed-
ing risk with the addition of bevacizumab.
More recent trials have looked at platinum/gemcitabine
versus platinum/pemetrexed as first-line therapy for advanced
NSCLC. A phase III trial randomized patients with advanced
NSCLC to receive carboplatin (AUC  5)  pemetrexed (500
mg/m2) versus carboplatin (AUC  5)  gemcitabine (1000
mg/m2) every 3 weeks19 and included 446 patients. In this study,
on the carboplatin/gemcitabine arm, which used the same che-
motherapy doses as in our trial (without the bevacizumab), the
OS was 7.0 months and grade 3/4 toxicity included 51%
neutropenia and 56% thrombocytopenia. Another phase III
trial compared cisplatin (75 mg/m2)  gemcitabine (1250
mg/m2) versus cisplatin (75 mg/m2)  pemetrexed (500
mg/m2) in 1725 patients with advanced NSCLC.20 The
cisplatin/gemcitabine arm had a RR of 28% and a median
PFS of 5.1 months. Of note, the OS for patients with
nonsquamous histology was significantly improved on the
cisplatin  pemetrexed arm, compared with the cisplatin/
gemcitabine arm (11.8 months versus 10.4 months, p  0.005).
Based on these results, the use of first-line platinum/
gemcitabine is less common for nonsquamous patients who
are now more frequently receiving platinum/pemetrexed or
platinum/taxane. The RR seen in our trial of 20% is
somewhat lower than expected, but the PFS of 8.7 months
and OS of 12.8 months are within expected ranges and
compare favorably to results found in phase III trials of the
combination of carboplatin/gemcitabine alone. No excess
in bleeding or infection was seen. Although the OS re-
ported in our trial may be artificially elevated by the high
proportion of nonsmokers and women, two groups of
patients with NSCLC with improved survival regardless of
therapy, we believe the combination of carboplatin/gem-
citabine/bevacizumab is a well tolerated, active regimen
that could be considered for patients with newly diagnosed
NSq-NSCLC in whom pemetrexed or paclitaxel are not
preferred chemotherapeutic options.
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